Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Müntze

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinical Case Reports|March 23, 2019
Long-term outcome after surgical repair of a rapid-grown ischemic ventricular aneurysm causing ventricular tachycardiaDaniel Gensler, Jonas Müntze, Peter Nordbeck
Cardiovascular Diagnosis and Therapy|May 10, 2021
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative reviewDaniel Oder, Jonas Müntze, Peter Nordbeck
The International Journal of Cardiovascular Imaging|September 4, 2023
Contrast-enhanced ultrasound for non-invasive differential diagnosis of unclear left atrial massMartin Christa, Jonas Müntze, Björn Lengenfelder, et al.
Postgraduate Medical Journal|December 19, 2018
Hot topics in Fabry diseaseTereza Cairns, Jonas Müntze, Judith Gernert, et al.
ESC Heart Failure|May 17, 2019
Impella CP use in patients with non-ischaemic cardiogenic shockOctavian Maniuc, Tim Salinger, Fabian Anders, et al.
Molecular Genetics and Metabolism|January 29, 2023
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyJonas Müntze, Kolja Lau, Markus Cybulla, et al.
Plos One|November 22, 2017
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Mario Cebulla, et al.
Medicine|May 26, 2018
Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational studyDaniel Oder, Dan Liu, Nurcan Üçeyler, et al.
Clinical Pharmacology and Therapeutics|December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 YearJonas Müntze, Daniel Gensler, Octavian Maniuc, et al.
Orphanet Journal of Rare Diseases|August 17, 2018
Characterization of vertigo and hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Dieter Schneider, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinical Case Reports|March 23, 2019
Long-term outcome after surgical repair of a rapid-grown ischemic ventricular aneurysm causing ventricular tachycardiaDaniel Gensler, Jonas Müntze, Peter Nordbeck
Cardiovascular Diagnosis and Therapy|May 10, 2021
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative reviewDaniel Oder, Jonas Müntze, Peter Nordbeck
The International Journal of Cardiovascular Imaging|September 4, 2023
Contrast-enhanced ultrasound for non-invasive differential diagnosis of unclear left atrial massMartin Christa, Jonas Müntze, Björn Lengenfelder, et al.
Postgraduate Medical Journal|December 19, 2018
Hot topics in Fabry diseaseTereza Cairns, Jonas Müntze, Judith Gernert, et al.
ESC Heart Failure|May 17, 2019
Impella CP use in patients with non-ischaemic cardiogenic shockOctavian Maniuc, Tim Salinger, Fabian Anders, et al.
Molecular Genetics and Metabolism|January 29, 2023
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter studyJonas Müntze, Kolja Lau, Markus Cybulla, et al.
Plos One|November 22, 2017
Cardiac and renal dysfunction is associated with progressive hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Mario Cebulla, et al.
Medicine|May 26, 2018
Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational studyDaniel Oder, Dan Liu, Nurcan Üçeyler, et al.
Clinical Pharmacology and Therapeutics|December 4, 2018
Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 YearJonas Müntze, Daniel Gensler, Octavian Maniuc, et al.
Orphanet Journal of Rare Diseases|August 17, 2018
Characterization of vertigo and hearing loss in patients with Fabry diseaseMaria Köping, Wafaa Shehata-Dieler, Dieter Schneider, et al.
Pageof 2